Log in Start free →
—
—
Health Care · NASDAQ NASDAQ · GILD

Gilead Sciences

$167.95 -$1.76 -1.05% CLOSE 11.12.26 AFTER HOURS $167.95
Convergence score
- / 5.0 —
+0.0 vs last report
Overall valuation
Overvalued
Aggregated across multiple horizons
Consensus target (12mo)
$174.77 +4.1%
Range $131.00 — $200.00
Sector
Health Care
NASDAQ · Tracked daily
Today's snapshot

Where the signals stand.

REPORT 11.12.26
UV Convergence Score
REPORT 11.12.26
-
/ 5.0
—
Consensus signal A
4.0
Consensus signal D
4.0
Analyst average
4.3
Multi-signal aggregate How CSR works →
Day Range
$167.93 – $171.69
52W Range
$116.88 – $176.58
Volume
4.2M
Avg Vol
6.0M
Mkt Cap
$208.31B
P/E
—
EPS (TTM)
—
Div Yield
1.93%
Beta
0.37
Today's convergence

Convergence score sits at - with overall valuation reading as overvalued. Drivers across the horizons inform the aggregate. Open the deep dives for valuation, analyst, or financial detail.

Valuation
Overvalued
CSR direction
—
Last close
$167.95
Sector
Health Care
Valuation
Three horizons
UPDATED 11.12.26
Short term
0–3 MO
No target —
Medium term
3–12 MO
No target —
Long term
12–36 MO
$129.32-23.0% Overvalued
Open valuation →
Analysts
Coverage & consensus
2 PANELS
Mean target (12mo)
$174.77 +4.1%
RANGE $131.00 — $200.00
Analyst consensus
Consensus rating Buy
Blended score 4.2 / 5
Analysts tracked 54
Open analysts →
Financials
Key metrics
LATEST
P/E
—
EPS (TTM)
—
Mkt Cap
$208.31B
Div Yield
1.93%
Beta
0.37
52W Range
$116.88 – $176.58
Open financials →
Reports
Login for history

Sign in to view the historical report archive for this stock.

Log in →
Valuation breakdown

Three horizons, one consensus.

UPDATED 11.12.26
Short term
0–3 MO
—
Consensus target
No target available
Medium term
3–12 MO
—
Consensus target
No target available
Long term
12–36 MO
Overvalued
Consensus target
$129.32 -23.0%

UVStocks in-house sector-relative valuation model.

Signal breakdown

What’s driving the score.

EACH SIGNAL RATED 1.0 — 5.0
Top-level breakdown
Valuation: PE Ratio: -PEG Ratio: -DE Ratio: -
Free Cash Flow: $10.68BPB Ratio: -PS Ratio: -Dividend: $0.82
Analyst coverage

Blended analyst consensus & targets.

2 PANELS · UPDATED 11.12.26
Analyst consensus RATING · SCORE · PANELS · ANALYSTS
Rating Blended score Panels Analysts
Buy 4.2 2 54
Price targets LOW · MEAN · MEDIAN · HIGH · UPSIDE
Coverage Low Mean Median High Upside
All panels $131.00 $174.77 $175.00 $200.00 +4.1%
Rating distribution STRONG BUY · BUY · HOLD · SELL · STRONG SELL
Coverage SB B H S SS
All panels 6 16 5 0 1
Rating trend CURRENT VS 1M / 2M / 3M
Period Rating Avg Analysts
Current — — —
1 Mo Ago — — —
2 Mo Ago — — —
3 Mo Ago — — —
Most recent analyst action LATEST DESK ACTION
Date
—
Firm
—
Action
—
Rating
—
Target
—
Related links
Financials

Full financial snapshot.

UPDATED 11.12.26
Quote snapshot 15 FIELDS
Prev Close
$169.73
Open
$171.18
Day Low
$167.93
Day High
$171.69
Bid
$161.24
Ask
$176.60
52W Low
$116.88
52W High
$176.58
50D Avg
$154.40
200D Avg
$141.44
Volume
4.2M
Avg Vol
6.0M
10D Avg Vol
7.6M
52W Change
35.57%
S&P 52W Change
13.09%
Valuation ratios 10 FIELDS
P/E (TTM)
—
P/E (Fwd)
16.58
PEG (Fwd)
2.29
P/S
6.72
P/B
15.98
Book Value
$10.51
EV/Revenue
7.31
EV/EBITDA
15.45
Mkt Cap
208.31B
Enterprise Val
226.51B
Profitability & returns 6 FIELDS
Profit Margin
-12.46%
Gross Margin
79.95%
Operating Margin
38.23%
EBITDA Margin
47.31%
Return on Assets
13.47%
Return on Equity
-22.45%
Growth 3 FIELDS
Revenue Growth (YoY)
6.80%
Earnings Growth (YoY)
-20.20%
Earnings Growth (Q)
-20.40%
Balance sheet & cash flow 11 FIELDS
Total Revenue
30.99B
EBITDA
14.66B
Total Cash
7.95B
Total Debt
26.23B
Cash / Share
$6.41
Revenue / Share
$24.95
Free Cash Flow
10.68B
Operating CF
14.48B
Debt / Equity
202.46
Current Ratio
1.38
Quick Ratio
1.08
Dividend 5 FIELDS
Fwd Dividend
3.28 (1.93%)
Dividend Yield
1.93%
Payout Ratio
43.46%
5Y Avg Yield
3.28%
Ex-Div Date
2026-12-15
Share statistics 7 FIELDS
Shares Out
1.24B
Float
1.24B
Shares Short
21.27M
% Short of Float
1.72%
Short Ratio
3.49
% Held Insiders
0.11%
% Held Institutions
91.48%
Calendar & events 5 FIELDS
Next Earnings
2026-10-29
Fiscal Year End
2025-12-31
Most Recent Qtr
2026-09-30
Last Split
2:1
Split Date
2013-01-28
Company 2 FIELDS
Industry
Drug Manufacturers - General
Employees
17,000